

New Vision in Ophthalmology

Harol Sten*

Sten H. *New Vision in Ophthalmology*. *Opth Clin Ther*. 2020;4(2): 1-2.

The *Ophthalmologist: Clinical and Therapeutic Journal* is an Open Access peer-reviewed journal internationally accessed. The journal publishes high-quality research papers, reviews, book reviews and short technical notes

INTRODUCTION

Open access (OA) is a set of principles and a range of practices through which research outputs are distributed online, free of cost or other access barriers [1]. With open access strictly defined (according to the 2001 definition), or libre open access, barriers to copying or reuse are also reduced or removed by applying an open license for copyright [1].

Ophthalmology [2] is a branch of medicine and surgery which deals with the diagnosis and treatment of eye disorders [3]. An ophthalmologist is a specialist in ophthalmology. The credentials include a degree in medicine, followed by additional four to five years of ophthalmology residency training. Ophthalmology residency training programs may require a one-year pre-residency training in internal medicine, pediatrics, or general surgery.

EDITORIAL

The *Ophthalmologist: Clinical and Therapeutic Journal* encourage researchers to flourish their research work worldwide. Journal has scope of publishing in areas including the most common diseases diagnosed and treated by ophthalmologists. These include Cataract, Glaucoma, Macular degeneration, Diabetic retinopathy, Dry eyes, Strabismus (misalignment/deviation of eyes), Proptosis (bulged eyes), Excessive tearing (tear duct obstruction), Uveitis, and Eye tumors.

The advance complex anatomical features of the eye and the presence of different ocular barriers has led to complications in the development of an effective treatment strategy for posterior segment diseases like diabetic retinopathy, age-related macular degeneration, retinal pigmentosa, etc., thus demanding the need for novel and innovative approaches. There are various treatment options available in the market which includes the new implants and drug delivery systems apart from the therapeutic agents which are benefiting the patients with modern improvements, enhanced formulations, targeted and long-term delivery. But they all still have numerous drawbacks which need to be addressed [8].

This peer-reviewed journal will remarkably contribute to that ideal of furthering the eye research field by evaluating and publishing the highest quality work from both professionals and professional groups alike. We believe that these potential findings will interest our readers to learn and gain new perspectives from the evidence generated by such research scholars. The Journal also hope to help further inspiration of leading thinkers in the comprehensive aspects of ongoing disease investigations. The journal serves as a bridge to connect physicians and researchers. We believe that the joint efforts will fill the gap between clinical and experimental

designed to help ophthalmology and optometry progress in all scientific fields in ophthalmology. The journal's broad scope is having an active Editorial Board and Reviewers. In my view *The Ophthalmologist: clinical and therapeutic journal* is a unique journal in its position to support the researchers as well as Ophthalmologists in all areas of ophthalmology and optometry science.

activities, therefore, significantly promote the research investigations and improve clinical cares for eye disorders [9].

Last but not the least, in this kind of dynamic environment with limited resources, we believe that the open flow of information will greatly push forward the understanding of the pathogenesis and development of eye disorders, followed by the advancement in exploration of new therapeutic avenues and improvement in vision care. To achieve this, the journal provides free open access online to the researchers worldwide and presents the content to the public with no barriers or constraints. Unfettered access to the sharing of such information will also significantly benefit the progression of vital research in both developing and underdeveloped countries. The *Ophthalmologist Clinical and Therapeutic Journal* offers the opportunity for scholars in these countries to be closely involved in updates regarding the most advanced knowledge about vision care and also to share their own findings in clinical practice and research studies; thusly, bringing up the attention and encouraging the research efforts from worldwide, promoting a potentially greater quality of life for people in all corners of the world.

The Journal is now moving forward towards COVID-19 articles by ophthalmologists which include how the viruses affect the patients suffering with various eye problems. Finally, Thanking the Authors, other Editorial board members and Reviewers for their tremendous contribution towards the journal. Mainly I would feel pleased of being as one of the Editorial board member.

The journal is here to support and give the opportunity to new ophthalmology and optometry scientists or students to show and promote their work. Hoping that this effort will be for the benefit of all researchers relating to ophthalmology, optometry and ophthalmic optics, the journal will provide the best motivation for further research work publishing.

REFERENCES

1. Peter S. Archived from the original 2007. Retrieved 2014. Open Access Overview.
2. ophthalmology. Retrieved 2015; Oxford Dictionary.
3. History of Ophthalmology.
4. What Causes Eye Problems?
5. Yolanda S. Subspecialties of Ophthalmology. News Medical Life Sciences 2017.
6. Acvo.com. Retrieved 2012.
7. Ecvo.org. Retrieved 2012.
8. Nagaraj R, Biju kumar DR, Mathew B, et al. A review on recent advancements in ophthalmology devices: Currently in market and

University of Toronto, Ontario, Canada.

*Correspondence: Dr. Harol Sten, Professor of Ophthalmology and Vision Sciences, University of Toronto, Ontario, Canada. E-mail: hastein1@hotmail.com

Received: July 10, 2020, Accepted: July 24, 2020, Published: July 31, 2020



This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact reprints@pulsus.com

under clinical trials. Journal of Drug Delivery Science and Technology
2019; 52:334-345

9. Pateras E. Advance Research in the Field of Optics and Optometry.
Oph Clin Ther. 2017; 1: 6.
